A Case for Pharma In-Licensing
Examining the internal rate of return for in-licensed compounds versus those developed by a firm's internal R&D, a new study by Mercer Management Consulting shows that while profit margins on in-house drugs are higher, they generate less cash over all due to the cost of capital incurred over long development lead times.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.